don't ask me where that stupid red smiley face came from...no...

First 118 Last

Share
Profile

Follow
turps

8,604 Posts.

83

05/07/18

14:01

Post #: 34161657
Share

Originally posted by turps ↑

just a reminder...

Phosphagenics' oxymorphone patch storms phase I

By Dylan Bushell-Embling
Thursday, 24 October, 2013

Phosphagenics (ASXOH) has completed the world’s first in-human trial of transdermal delivery of oxymorphone, with a phase I trial of its TPM/oxymorphone patch.
The patch was shown to deliver therapeutic plasma concentrations of oxymorphone in all 12 healthy volunteer subjects.
The participants each received repeated applications of a three-day sustained release TPM/oxymorphone pain patch, mimicking a real-life pain medication regime.
All 12 subjects demonstrated oxymorphone plasma concentrations well above the threshold therapeutic concentrations produced by the oral long-acting or extended-release dosage form of oxymorphone, Opana ER, within the first application period.
Phosphagenics said the results show that the maximum plasma concentration in subjects can be as high as that produced by the highest-strength Opana ER tablet, 40 mg. But TPM/oxymorphone only contains about 25% of the oxymorphone used in high dosage strengths of the pill form, reducing the potential for abuse.
“The importance of the success of this trial cannot be overstated. While we were confident going into the trial, the magnitude of the oxymorphone concentration in plasma surpassed our expectations,” Phosphagenics Chief Scientific Officer Dr Paul Gavin said.
“Not only can the patch deliver therapeutic amounts of oxymorphone, the results suggest that the patch can compete with the therapeutic value of the higher dosage strengths of the oral product and surpass them with respect to bioavailability.”
Phosphagenics CEO Harry Rosen said on the strength of the results that the company will shift its emphasis for a planned phase II trial from proving the product’s analgesic capabilities to defining the dosing regimes to be used with the product.
“The questions as to whether our opioid patch technology works have been categorically answered by these results. The task is now to work with our pain experts and regulatory consultants to progress the project through the next phases of the clinical trial and regulatory processes, as well as licensing discussions.”
The company aims to commence the phase II trial in mid-2014. Phosphagenics projects that peak sales of a successfully commercialised TPM/oxycodone could reach as high as $1.4 billion a year.
Phosphagenics also plans to commence a phase II trial of another opioid pain patch, TPM/oxycodone, in 2014.
Phosphagenics (ASXOH) shares were trading 42.86% higher at $0.15 as of around 2.30 pm on Thursday.

Related Articles

we've got the patches ready....ph2 is on the cards

Expand

don't ask me where that stupid red smiley face came from...no idea!

POH Price at posting: 1.6¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

HIQ

Mouthguard concussion sensor tech developer HIT IQ wins second US patent

The Rising Tide: How institutional adoption is shaping the future of crypto

TRE

Toubani raises $10M to see Mali's Koubada Gold Project through to DFS

SVL

Silver Mines pushing ahead with NSW Bowdens project despite green group setback over power lines

There are more pages in this discussion • 1 more message in this thread...

First 118 Last

Add AVE (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $9.507M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
48	86877619	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	60020911	20

View Market Depth

No.	Vol.	Price($)
48	86877619	0.002
22	69095508	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	60020911	20
0.004	17122582	17
0.005	22833333	10
0.006	19255067	9
0.007	5722471	6

Last trade - 16.12pm 21/08/2024 (20 minute delay)

AVE (ASX) Chart

Day chart unavailable

don't ask me where that stupid red smiley face came from...no...

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Mouthguard concussion sensor tech developer HIT IQ wins second US patent

The Rising Tide: How institutional adoption is shaping the future of crypto

Toubani raises $10M to see Mali's Koubada Gold Project through to DFS

Silver Mines pushing ahead with NSW Bowdens project despite green group setback over power lines

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

don't ask me where that stupid red smiley face came from...no...

Top Stories

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Mouthguard concussion sensor tech developer HIT IQ wins second US patent

The Rising Tide: How institutional adoption is shaping the future of crypto

Toubani raises $10M to see Mali's Koubada Gold Project through to DFS

Silver Mines pushing ahead with NSW Bowdens project despite green group setback over power lines

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News